Jianhang Bao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianhang Bao has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Xinyan Huang
Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY 14642, USA
3 shared publications - Jin Xiao
Eastman Institute for Oral Health University of Rochester Medical Center Rochester New York USA
2 shared publications - Shuangyue Wu
School of Stomatology, Henan University, Kaifeng 475001, China
2 shared publications - Tong Tong Wu
Affiliation Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, New York, United States of America
2 shared publications - Xingyi Lu
Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY 14642, USA
2 shared publications - Yan Zeng
Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY 14642, USA
2 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Elsevier in International Dental Journal
- Vol. 76 (6)
Cannabidiol and Cannabigerol Modulate Cariogenic Virulence in Cross-Kingdom Biofilms In Vitro
- 19 September 2026
- Published by Elsevier in International Dental Journal
- Vol. 76 (6)
Open AccessCannabidiol and Cannabigerol Modulate Cariogenic Virulence in Cross-Kingdom Biofilms In Vitro
- Open Access
- 3 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1221
Therapeutic Potential of Cannabidiol in Dysbiosis-Related Oral Biofilm Diseases: Antibiofilm, Antivirulence and Host Response Evidence
Dysbiosis-related oral biofilm diseases, particularly dental caries and periodontal diseases, pose major global health challenges because ecological shifts within oral microbial communities enhance biofilm virulence, resilience, and host inflammatory responses. Cannabidiol (CBD), a non-psychoactive phytocannabinoid with antimicrobial, antibiofilm, immunomodulatory, and antioxidant properties, has attracted increasing interest as an investigational, ecology-oriented adjunct for oral health applications. This narrative review evaluates current antibiofilm, antivirulence, and host response evidence for CBD in dysbiosis-related oral biofilm diseases, with emphasis on dental caries and periodontal diseases and selected supportive evidence from other oral biofilm-associated conditions. Current evidence suggests that CBD can inhibit biofilm formation, attenuate cariogenic and fungal virulence traits, modulate periodontal inflammation and immunity, and support tissue-protective responses. However, most evidence remains preclinical and model-dependent, particularly in caries research, and CBD’s hydrophobicity, limited stability, uncertain dose windows, and incomplete microbiome-level evidence remain major barriers to translation. Future studies should clarify CBD’s ecological effects on oral microbial communities, define clinically relevant dosing and exposure timing, and develop oral-retentive delivery systems.
- 3 August 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1221
Open AccessTherapeutic Potential of Cannabidiol in Dysbiosis-Related Oral Biofilm Diseases: Antibiofilm, Antivirulence and Host Response Evidence
Dysbiosis-related oral biofilm diseases, particularly dental caries and periodontal diseases, pose major global health challenges because ecological shifts within oral microbial communities enhance biofilm virulence, resilience, and host inflammatory responses. Cannabidiol (CBD), a non-psychoactive phytocannabinoid with antimicrobial, antibiofilm, immunomodulatory, and antioxidant properties, has attracted increasing interest as an investigational, ecology-oriented adjunct for oral health applications. This narrative review evaluates current antibiofilm, antivirulence, and host response evidence for CBD in dysbiosis-related oral biofilm diseases, with emphasis on dental caries and periodontal diseases and selected supportive evidence from other oral biofilm-associated conditions. Current evidence suggests that CBD can inhibit biofilm formation, attenuate cariogenic and fungal virulence traits, modulate periodontal inflammation and immunity, and support tissue-protective responses. However, most evidence remains preclinical and model-dependent, particularly in caries research, and CBD’s hydrophobicity, limited stability, uncertain dose windows, and incomplete microbiome-level evidence remain major barriers to translation. Future studies should clarify CBD’s ecological effects on oral microbial communities, define clinically relevant dosing and exposure timing, and develop oral-retentive delivery systems.
- Open Access
Dose-Dependent Inhibitory Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans-Candida albicans Cross-Kingdom Microorganisms
Dental caries is one of the most common chronic diseases worldwide. Streptococcus mutans and Candida albicans are two major pathogens associated with dental caries. Several recent studies revealed that Lactobacillus plantarum inhibits S. mutans and C. albicans in biofilms and in a rodent model of dental caries. The aim of this study was to investigate the dose-dependent effect of L. plantarum against S. mutans and C. albicans in a planktonic model that simulated a high-caries-risk clinical condition. Mono-, dual-, and multi-species models were utilized, with five doses of L. plantarum (ranging from 1.0 × 104 to 1.0 × 108 CFU/mL). Real-time PCR was used to assess the expression of the virulence genes of C. albicans and S. mutans and the genes of L. plantarum. Student’s t-tests and one-way ANOVA, followed by post hoc tests, were employed to compare the cell viability and gene expression among groups. A dose-dependent inhibition on C. albicans and S. mutans was observed with increased dosages of L. plantarum. L. plantarum at 108 CFU/mL demonstrated the highest antibacterial and antifungal inhibitory effect in the dual- and multi-species models. Specifically, at 20 h, the growth of C. albicans and S. mutans was suppressed by 1.5 and 5 logs, respectively (p < 0.05). The antifungal and antibacterial effects were attenuated in lower doses of L. plantarum (104–107 CFU/mL). The expression of C. albicans HWP1 and ECE 1 genes and S. mutans lacC and lacG genes were significantly downregulated with an added 108 CFU/mL of L. plantarum (p < 0.05). The addition of 108 CFU/mL L. plantarum further inhibited the hyphae or pseudohyphae formation of C. albicans. In summary, L. plantarum demonstrated dose-dependent antifungal and antibacterial effects against C. albicans and S. mutans. L. plantarum emerged as a promising candidate for the creation of novel antimicrobial probiotic products targeting dental caries prevention. Further research is warranted to identify the functional metabolites produced by L. plantarum at different dosages when interacting with C. albicans and S. mutans.
Open AccessDose-Dependent Inhibitory Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans-Candida albicans Cross-Kingdom Microorganisms
Dental caries is one of the most common chronic diseases worldwide. Streptococcus mutans and Candida albicans are two major pathogens associated with dental caries. Several recent studies revealed that Lactobacillus plantarum inhibits S. mutans and C. albicans in biofilms and in a rodent model of dental caries. The aim of this study was to investigate the dose-dependent effect of L. plantarum against S. mutans and C. albicans in a planktonic model that simulated a high-caries-risk clinical condition. Mono-, dual-, and multi-species models were utilized, with five doses of L. plantarum (ranging from 1.0 × 104 to 1.0 × 108 CFU/mL). Real-time PCR was used to assess the expression of the virulence genes of C. albicans and S. mutans and the genes of L. plantarum. Student’s t-tests and one-way ANOVA, followed by post hoc tests, were employed to compare the cell viability and gene expression among groups. A dose-dependent inhibition on C. albicans and S. mutans was observed with increased dosages of L. plantarum. L. plantarum at 108 CFU/mL demonstrated the highest antibacterial and antifungal inhibitory effect in the dual- and multi-species models. Specifically, at 20 h, the growth of C. albicans and S. mutans was suppressed by 1.5 and 5 logs, respectively (p < 0.05). The antifungal and antibacterial effects were attenuated in lower doses of L. plantarum (104–107 CFU/mL). The expression of C. albicans HWP1 and ECE 1 genes and S. mutans lacC and lacG genes were significantly downregulated with an added 108 CFU/mL of L. plantarum (p < 0.05). The addition of 108 CFU/mL L. plantarum further inhibited the hyphae or pseudohyphae formation of C. albicans. In summary, L. plantarum demonstrated dose-dependent antifungal and antibacterial effects against C. albicans and S. mutans. L. plantarum emerged as a promising candidate for the creation of novel antimicrobial probiotic products targeting dental caries prevention. Further research is warranted to identify the functional metabolites produced by L. plantarum at different dosages when interacting with C. albicans and S. mutans.
- Open Access
Anti-cariogenic Properties of Lactobacillus plantarum in the Utilization of Galacto-Oligosaccharide
Ecological approaches can help to correct oral microbial dysbiosis and drive the advent and persistence of a symbiotic oral microbiome, which benefits long-term dental caries control. The aim of this study was to investigate the impact of the prebiotic Galacto-oligosaccharide (GOS) on the growth of probiotics L. plantarum 14,917 and its effect on the inhibitory ability of L. plantarum 14,917 against the growth of Streptococcus mutans and Candida albicans in an in vitro model. Single-species growth screenings were conducted in TSBYE broth with 1% glucose and 1–5% GOS. Interaction experiments were performed using duo- and multi-species models with inoculation of 105 CFU/mL S. mutans, 103 CFU/mL C. albicans, and 108 CFU/mL L. plantarum 14,917 under 1%, 5% GOS or 1% glucose. Viable cells and pH changes were measured. Real-time PCR was utilized to assess expression of C. albicans and S. mutans virulence genes. Six replicates were used for each group. Student’s t-test, one-way ANOVA, and Kruskal-Wallis were employed to compare the outcomes of different groups. GOS significantly inhibited the growth of C. albicans and S. mutans in terms of growth quantity and speed when the two strains were grown individually. However, GOS did not affect the growth of L. plantarum 14,917. Moreover, 1% and 5% GOS enhanced the anti-fungal performance of L. plantarum 14,917 in comparison to 1% glucose. GOS as the carbon source resulted in a less acidic environment in the C. albicans and S. mutans duo-species model and multispecies model where L. plantarum 14,917 was added. When GOS was utilized as the carbohydrate substrate, S. mutans and C. albicans had a significant reduction in the expression of the HWP1, ECE1, atpD, and eno genes (p < 0.05). To our knowledge, this is the first study that reported the ability of GOS to neutralize S. mutans-C. albicans high caries of medium pH and to disrupt virulence gene expression. Moreover, as a prebiotic, GOS augmented the inhibitory ability of L. plantarum against C. albicans in vitro. The current study revealed the anti-caries potential of prebiotics GOS and shed light on novel caries prevention strategies from the perspective of prebiotics and probiotics. These findings provide a rationale for future biofilm or clinical studies to elucidate the effect of GOS on modulating oral microbiota and caries control.
Open AccessAnti-cariogenic Properties of Lactobacillus plantarum in the Utilization of Galacto-Oligosaccharide
Ecological approaches can help to correct oral microbial dysbiosis and drive the advent and persistence of a symbiotic oral microbiome, which benefits long-term dental caries control. The aim of this study was to investigate the impact of the prebiotic Galacto-oligosaccharide (GOS) on the growth of probiotics L. plantarum 14,917 and its effect on the inhibitory ability of L. plantarum 14,917 against the growth of Streptococcus mutans and Candida albicans in an in vitro model. Single-species growth screenings were conducted in TSBYE broth with 1% glucose and 1–5% GOS. Interaction experiments were performed using duo- and multi-species models with inoculation of 105 CFU/mL S. mutans, 103 CFU/mL C. albicans, and 108 CFU/mL L. plantarum 14,917 under 1%, 5% GOS or 1% glucose. Viable cells and pH changes were measured. Real-time PCR was utilized to assess expression of C. albicans and S. mutans virulence genes. Six replicates were used for each group. Student’s t-test, one-way ANOVA, and Kruskal-Wallis were employed to compare the outcomes of different groups. GOS significantly inhibited the growth of C. albicans and S. mutans in terms of growth quantity and speed when the two strains were grown individually. However, GOS did not affect the growth of L. plantarum 14,917. Moreover, 1% and 5% GOS enhanced the anti-fungal performance of L. plantarum 14,917 in comparison to 1% glucose. GOS as the carbon source resulted in a less acidic environment in the C. albicans and S. mutans duo-species model and multispecies model where L. plantarum 14,917 was added. When GOS was utilized as the carbohydrate substrate, S. mutans and C. albicans had a significant reduction in the expression of the HWP1, ECE1, atpD, and eno genes (p < 0.05). To our knowledge, this is the first study that reported the ability of GOS to neutralize S. mutans-C. albicans high caries of medium pH and to disrupt virulence gene expression. Moreover, as a prebiotic, GOS augmented the inhibitory ability of L. plantarum against C. albicans in vitro. The current study revealed the anti-caries potential of prebiotics GOS and shed light on novel caries prevention strategies from the perspective of prebiotics and probiotics. These findings provide a rationale for future biofilm or clinical studies to elucidate the effect of GOS on modulating oral microbiota and caries control.